| PRECLINICAL | evidence | Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice. | Semaglutide | — | 2026-07-11 |
| PRECLINICAL | evidence | Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial. | Semaglutide | — | 2026-07-11 |
| PRECLINICAL | evidence | Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes. | Semaglutide | — | 2026-07-11 |
| PRECLINICAL | evidence | The Periprocedural Safety of Continued GLP-1 Receptor Agonist Prior to Cardiac Catheterization. | Semaglutide | — | 2026-07-11 |
| PRECLINICAL | evidence | Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss. | Semaglutide | — | 2026-07-10 |
| PRECLINICAL | evidence | Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report. | Semaglutide | — | 2026-07-10 |
| PRECLINICAL | evidence | GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence. | Semaglutide | — | 2026-07-10 |
| PRECLINICAL | evidence | Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis. | Semaglutide | — | 2026-07-09 |
| PRECLINICAL | evidence | Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review. | Semaglutide | — | 2026-07-09 |
| PRECLINICAL | evidence | Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults. | Semaglutide | — | 2026-07-09 |
| PRECLINICAL | evidence | GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis. | Semaglutide | — | 2026-07-09 |
| PRECLINICAL | evidence | Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025. | Wegovy | — | 2026-07-09 |
| PRECLINICAL | evidence | Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients. | Semaglutide | — | 2026-07-09 |
| PRECLINICAL | evidence | National trends in prescription drug expenditures and projections for 2026. | Semaglutide | — | 2026-07-08 |
| PRECLINICAL | evidence | The neuroendocrine-appetite-mental health triangle in PMOS: Implications for GLP-1 receptor agonist therapy. | Semaglutide | — | 2026-07-08 |
| PRECLINICAL | evidence | Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis. | Semaglutide | — | 2026-07-08 |
| PRECLINICAL | evidence | GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways. | Semaglutide | — | 2026-07-08 |
| PRECLINICAL | evidence | Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. | Semaglutide | Weight & fat loss | 2026-07-08 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis. | Semaglutide | — | 2026-07-08 |
| PRECLINICAL | evidence | Short-Term HbA1c Non-Inferiority of Synthetic Semaglutide Should Not Be Conflated With Full Therapeutic Interchangeability. | Semaglutide | — | 2026-07-08 |
| PRECLINICAL | evidence | Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes. | Semaglutide | — | 2026-07-08 |
| PRECLINICAL | evidence | Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists. | Semaglutide | — | 2026-07-08 |
| PRECLINICAL | evidence | Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification. | Semaglutide | Inflammation | 2026-07-07 |
| PRECLINICAL | evidence | Harnessing the Reactivity of Sulfinate Salts With Cystine: An Umpolung Approach to Residue-Specific Peptide Modification. | Semaglutide | — | 2026-07-07 |
| PRECLINICAL | evidence | Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer. | Semaglutide | — | 2026-07-07 |
| PRECLINICAL | evidence | GLP-1 and MASH: When weight loss isn't the whole story. | Semaglutide | Weight & fat loss | 2026-07-07 |
| PRECLINICAL | evidence | Brain Neuromodulation via Endoscopic Gastric Implant Improves Glycemic Control in Insulin-Dependent Type-2 Diabetes: First-in-Human Feasibility and Autonomic Response Study. | Semaglutide | — | 2026-07-07 |
| PRECLINICAL | evidence | GLP-1 medications: use and interest in a representative survey of Finns. | Ozempic | — | 2026-07-07 |
| PRECLINICAL | evidence | Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss. | Semaglutide | — | 2026-07-07 |
| PRECLINICAL | evidence | Wegovy weight loss pill now available to UK patients-how will it affect doctors? | Wegovy | — | 2026-07-07 |
| PRECLINICAL | evidence | Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis. | Semaglutide | — | 2026-07-07 |
| PRECLINICAL | evidence | Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial. | Semaglutide | — | 2026-07-06 |
| PRECLINICAL | evidence | Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study. | Wegovy | — | 2026-07-06 |
| PRECLINICAL | evidence | Comment on 'The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies'. | Semaglutide | — | 2026-07-06 |
| PRECLINICAL | evidence | A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice. | Semaglutide | — | 2026-07-06 |
| PRECLINICAL | evidence | Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials. | Semaglutide | — | 2026-07-06 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study. | Semaglutide | — | 2026-07-06 |
| PRECLINICAL | evidence | Letter: Non-Invasive Tests After Semaglutide in MASH as Disease-Activity Readouts Rather Than Response Biomarkers. | Semaglutide | — | 2026-07-05 |
| PRECLINICAL | evidence | Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis. | Semaglutide | — | 2026-07-04 |
| PRECLINICAL | evidence | GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles. | Semaglutide | — | 2026-07-04 |
| PRECLINICAL | evidence | GLP-1 receptor agonists in pediatric obesity. | Semaglutide | — | 2026-07-04 |
| PRECLINICAL | evidence | Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study. | Semaglutide | — | 2026-07-04 |
| PRECLINICAL | evidence | Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate. | Semaglutide | — | 2026-07-03 |
| PRECLINICAL | evidence | Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations. | Semaglutide | — | 2026-07-03 |
| PRECLINICAL | evidence | Current Concepts in Perioperative Guidance and Outcomes in Hand Surgery Patients Taking Glucagon-Like Peptide-1 Receptor Agonists. | Semaglutide | — | 2026-07-03 |
| PRECLINICAL | evidence | GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease. | Semaglutide | — | 2026-07-03 |
| PRECLINICAL | evidence | Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology. | Ozempic | — | 2026-07-03 |
| PRECLINICAL | evidence | Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence. | Semaglutide | — | 2026-07-03 |
| PRECLINICAL | evidence | PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction. | Semaglutide | — | 2026-07-03 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists in Cardiac Surgery: From Metabolic Drug to Potential Perioperative Cardioprotective Agent. | Semaglutide | — | 2026-07-03 |